876461-31-3

Basic information

• Product Name: CyclohexanaMine, 4-[4-(cyclopropylMethyl)-1-piperazinyl]-, trans-
• Synonyms: CyclohexanaMine, 4-[4-(cyclopropylMethyl)-1-piperazinyl]-, trans-;trans-4-(4-(CyclopropylMethyl)piperazin-1-yl)cyclohexanaMine
• CAS NO: 876461-31-3
• Molecular Formula: C₁₄H₂₇N₃
• Molecular Weight: 237.38428
• Mol File: 876461-31-3.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 326.1°C at 760 mmHg
• Flash Point: 148.9°C
• Appearance: /
• Density: 1.063g/cm³
• Vapor Pressure: 0.00022mmHg at 25°C
• Refractive Index: 1.552
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: CyclohexanaMine, 4-[4-(cyclopropylMethyl)-1-piperazinyl]-, trans-(CAS DataBase Reference)
• NIST Chemistry Reference: CyclohexanaMine, 4-[4-(cyclopropylMethyl)-1-piperazinyl]-, trans-(876461-31-3)
• EPA Substance Registry System: CyclohexanaMine, 4-[4-(cyclopropylMethyl)-1-piperazinyl]-, trans-(876461-31-3)

Safety Data

• Hazardous Substances Data: 876461-31-3(Hazardous Substances Data)

Usage

General Description

Cyclohexanamine, 4-[4-(cyclopropylmethyl)-1-piperazinyl]-, trans- is a chemical compound with a cyclic structure and a piperazine functional group. It is a trans isomer of 4-[4-(cyclopropylmethyl)-1-piperazinyl]-cyclohexanamine and is commonly used in the pharmaceutical industry for its potential therapeutic properties. Cyclohexanamine, 4-[4-(cyclopropylmethyl)-1-piperazinyl]-, trans- may have applications in the development of new medications for various conditions, and its unique chemical structure may make it valuable for research and development purposes. As with any chemical compound, proper handling and precautions should be taken when working with cyclohexanamine, 4-[4-(cyclopropylmethyl)-1-piperazinyl]-, trans- to ensure safety and regulatory compliance.

InChI:InChI=1/C14H27N3/c15-13-3-5-14(6-4-13)17-9-7-16(8-10-17)11-12-1-2-12/h12-14H,1-11,15H2/t13-,14-

Upstream product

• 57184-25-5 1-cyclopropylmethylpiperazine 
• 149506-79-6 4-(dibenzylamino)cyclohexanone 
• 373608-42-5 1-(cyclopropylmethyl)piperazine dihydrochloride 
• 149506-81-0 trans-4-(dibenzylamino)cyclohexanol 
• 50910-54-8 trans-4-aminocyclohexanol hydrochloride 
• 755039-89-5 (trans)-N,N-dibenzyl-4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexanamine 
• 17578-82-4 N-(2-oxocyclohexyl)acetamide 
• 882660-40-4 C₁₆H₂₉N₃O 
• 27489-62-9 trans-4-hydroxycyclohexylamine 
• 373608-50-5 4-cyclopropylmethylpiperazine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1280665-32-8 7-[[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-N-[(trans)-4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl]-2,3-dihydrobenzofuran-4-carboxamide 
• 1280665-50-0 N-[(trans)-4-[4-(Cyclopropylmethyl)piperazin-1-yl]cyclohexyl]-7-[[(7S)-7-ethyl-8-isopropyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-2,3-dihydrobenzofuran-4-carboxamide 
• 882660-39-1 C₂₂H₃₄N₄O₂ 
• 755038-65-4 Volasertib 
• 882660-36-8 C₂₂H₃₂N₄O₄ 

Relevant articles and documents

CYCLIN-DEPENDENT KINASE INHIBITING COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS

This invention is in the area of cell cycle inhibiting compounds for the treatment of disorders involving abnormal cellular proliferation, and include selective CDK2 inhibitors for medical therapy and their pharmaceutically acceptable salts and compositions.

DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF

Dihydroperidinone derivatives, preparation process and pharmaceutical use thereof are disclosed. Specially, new dihydroperidinone derivatives represented by general formula (I), wherein each substituent of the general formula (I) is defined as in the description, their preparation process, pharmaceutical compositions comprising said derivatives and their use as therapeutical agents, especially as Plk kinase inhibitors are disclosed.

COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION

The present invention relates to a pharmaceutical composition for the treatment of diseases which involve cell proliferation. The invention also relates to a method for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I) wherein the groups L, R1, R2, R3, R4 and R5 have the meanings given in the claims and specification, optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of Formula (I) and of an effective amount of an active compound 2 and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.